Investigating the role of noncoding RNAs in acute myeloid leukemia
Biology and Targeting of noncoding RNAs in AML
['FUNDING_R01'] · UNIVERSITY OF UTAH · NIH-10932390
This study is looking at how certain molecules called long noncoding RNAs might help acute myeloid leukemia (AML) cells grow, with the hope of finding new ways to treat patients with this type of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-10932390 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the biology of acute myeloid leukemia (AML) by exploring the role of long noncoding RNAs (lncRNAs) in the disease. It aims to identify how these lncRNAs, particularly HOXB-AS3, contribute to the proliferation of AML cells and their potential as therapeutic targets. The study involves both in vitro experiments with AML cell lines and in vivo experiments using patient-derived xenograft models to assess the effects of silencing specific lncRNAs on cancer progression and patient survival. By uncovering these mechanisms, the research seeks to pave the way for new treatment strategies for AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with cytogenetically normal AML and mutations in the NPM1 gene.
Not a fit: Patients with other types of leukemia or those who do not have the specific genetic mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that improve survival rates for patients with acute myeloid leukemia.
How similar studies have performed: While the role of lncRNAs in solid tumors has been explored, this research is pioneering in its focus on their function in acute myeloid leukemia, making it a novel approach.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARZON, RAMIRO — UNIVERSITY OF UTAH
- Study coordinator: GARZON, RAMIRO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.